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Background: For children with heart failure (HF), the placement of a ventricular assist device (VAD) as a bridge to recovery or transplant is 
becoming a common strategy. Pts with HF are known to be at increased risk for the development of arrhythmias. How VADs affect the development 
or progression of arrhythmias or how arrhythmias affect the clinical course of this population is not well described.
Methods: All pts placed on a VAD at our institution were reviewed (7/98-8/11). We reviewed pt demographics, etiology of HF, details of VAD 
support, arrhythmia history, and outcomes. Pts placed on Berlin Heart Excor devices were excluded.
Results: 45 pts had a total of 51 devices (19 Bio-Medicus, 11 HeartMate II, 11 Thoratec, 4 RotaFlow, 3 Debakey MicroMed, and 3 Tandem Heart). 
The mean age at VAD placement was 11.2 +/- 6.3 years. Median duration of VAD support was 17 days (range 2-260). Etiology of HF included 
cardiomyopathy (16), transplant rejection (13), myocarditis (6), and other diagnoses including congenital heart disease (10). Nineteen pts went on 
to transplant from VAD; 15 pts weaned from VAD; 10 pts died while on VAD (including 1 transplanted from VAD previously); and 2 pts remained on 
VAD. Twenty-nine pts (64%) had an arrhythmia during the course of care. Eighteen of these (62%) had an arrhythmia prior to VAD placement. Ten pts 
without prior arrhythmias developed new arrhythmias on VAD. VT was by far the most common arrhythmia (23/29, 79%). Eighteen pts were placed 
on antiarrhythmics, most commonly amiodarone, and 11 were monitored without initiation of therapy. There was no correlation between arrhythmias 
and risk of death or transplantation (p=0.21). Fifteen pts who weaned from VAD were followed for a mean of 4.6 ± 4 years. Arrhythmias persisted in 
9/15 (60%) requiring chronic antiarrhythmic therapy with 7/9 (78%) having ventricular arrhythmias. Pts with continued LV dysfunction were more 
likely to have arrhythmias in follow-up (p<0.02).
Conclusion: Arrhythmias are common in children requiring VAD support with ventricular arrhythmias predominating. They may complicate acute 
management and frequently persist in follow-up for those able to wean from VAD. This group may require close monitoring.
